Axiom International Investors LLC DE Sells 51,370 Shares of Immunomedics, Inc. (IMMU)

Axiom International Investors LLC DE decreased its position in Immunomedics, Inc. (NASDAQ:IMMU) by 38.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,480 shares of the biopharmaceutical company’s stock after selling 51,370 shares during the period. Axiom International Investors LLC DE’s holdings in Immunomedics were worth $1,718,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IMMU. First Allied Advisory Services Inc. bought a new position in Immunomedics during the second quarter worth about $205,000. Gideon Capital Advisors Inc. bought a new position in Immunomedics during the third quarter worth about $229,000. Jasper Ridge Partners L.P. bought a new position in Immunomedics during the second quarter worth about $259,000. Parametrica Management Ltd bought a new position in Immunomedics during the third quarter worth about $281,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in Immunomedics during the third quarter worth about $297,000. Hedge funds and other institutional investors own 75.96% of the company’s stock.

A number of equities analysts have issued reports on IMMU shares. BidaskClub cut Immunomedics from a “buy” rating to a “hold” rating in a report on Saturday, August 4th. B. Riley raised their target price on Immunomedics from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, August 24th. Zacks Investment Research upgraded Immunomedics from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. TheStreet cut Immunomedics from a “c-” rating to a “d+” rating in a report on Tuesday, September 11th. Finally, Goldman Sachs Group started coverage on Immunomedics in a report on Monday, September 17th. They set a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and a consensus target price of $38.43.

Shares of IMMU opened at $20.09 on Friday. The company has a current ratio of 13.45, a quick ratio of 13.45 and a debt-to-equity ratio of 0.06. Immunomedics, Inc. has a 1 year low of $8.68 and a 1 year high of $27.33. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -19.50 and a beta of 1.93.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same period last year, the business posted ($0.97) EPS. As a group, equities analysts predict that Immunomedics, Inc. will post -1.2 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/12/02/axiom-international-investors-llc-de-sells-51370-shares-of-immunomedics-inc-immu.html.

Immunomedics Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Featured Article: Do stock splits help investors?

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit